Our Mission
Driven by innovative research, our aim is to bring accessible, affordable and life-changing treatments to patients with cardiopulmonary diseases, offering them new hope and bettering their lives.
ATXA'S INITIAL FOCUS
PULMONARY ARTERIAL HYPERTENSION
Current therapies for PAH typically act to increase vasodilation to lower pulmonary vascular resistance and improve exercise capacity. They do little to treat the other major clinical features of the disease or to reduce disease progression. Patient outcomes remain poor - and these current therapies often have severe side effects.
Therefore, there is an urgent unmet medical need for new targets and therapeutic drugs that offer greater tolerability/compliance and overall efficacy.
NEW HOPE FOR THE PAH PATIENT
AND OTHER CARDIOPULMONARY DISEASE PATIENTS
NTP42
A First-In-Class Drug with a Novel Mechanism of Action
A small molecule drug that inhibits the thromboxane prostanoid receptor (TP).
NTP42
Treats All PAH Disease Hallmarks
Targeting the causes and symptoms of PAH.
NTP42
Safe & Well-tolerated
Alone or in combination with current standard-of-care drugs.
NTP42
Platform Disease Potential
High Potential to treat Related Cardiopulmonary Diseases, such as Heart Failure, ILD, IPF & COVID-19 complications.
